ReviewPublished 15 July 2026PSMA-targeted radioligand therapy in advanced prostate cancer: a narrative review of ^177Lu-PSMA, emerging ^225Ac-PSMA strategies, and therapeutic sequencingNatalia Gierulska · Nina Jankowska · Adrianna Kwiatkowska · Piotr Kuchno · Kinga Łysak · Katarzyna Szklener · Kamil Kośmider · Magdalena SkórzewskaOncology Reviewsdoi 10.3389/or.2026.1834484
ReviewPublished 12 May 2026Uncertain magnitude of benefit of early second-generation androgen receptor antagonist treatment in advanced prostate cancerEmma K. van de Weerdt · Ashley J. Duits · Michael J. Samson · John-John B. SchnogOncology Reviewsdoi 10.3389/or.2026.1750202
Original ResearchPublished 12 January 2026Social determinants of health associated with the clinicopathological presentation of patients with prostate cancer in KenyaCharles Waihenya · S. M. Thumbi · Daniel Kinyuru Ojuka · Camille Ragin · Charnita Zeigler-JohnsonFrontiers in Cancer Control and Societydoi 10.3389/fcacs.2025.1649686
